Consensus

DOI: 10.4244/EIJ-JAA-202501

Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society

Jean-Claude Deharo1,2; Julien Dreyfus3; Maria-Grazia Bongiorni4; Haran Burri5; Pascal Defaye6; Michael Glikson7; Nigel Lever8; Antonio Mangieri9; Blandine Mondésert10; Jens Cosedis Nielsen11,12; Maully Shah13; Christoph Thomas Starck14; Archana Rao15; Christophe Leclercq16; Fabien Praz17

Abstract

Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI. Graphical abstract.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 22
Nov 14, 2025
Volume 21 Number 22
View full issue


Key metrics

Suggested by Cory

Viewpoint

Feb 16, 2026
PCR: a new era dawns
Prendergast B
free

Editorial

10.4244/EIJ-D-25-01330 Feb 16, 2026
Aspirin discontinuation after ACS: timing the transition to ticagrelor monotherapy
Gragnano F and Calabrò P
free

Editorial

10.4244/EIJ-D-25-01331 Feb 16, 2026
Will the dream of "leave nothing behind" remain a utopia if we forget to optimise the systemic medical therapy?
Wykrzykowska J and Kraak R
free

State-of-the-Art

10.4244/EIJ-D-25-00598 Feb 16, 2026
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima A et al
free

Original Research

10.4244/EIJ-D-25-00618 Feb 16, 2026
Hertz contact intravascular lithotripsy for calcified coronary artery disease: the PINNACLE-I trial
Verheye S et al
open access

Flashlight

10.4244/EIJ-D-25-00431 Feb 16, 2026
A novel spacer for transcatheter treatment of tricuspid regurgitation
Barbieri F et al
open access
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved